{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T22:23:29Z","timestamp":1794349409046,"version":"4.9.0"},"reference-count":63,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100025603","name":"Long Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100025603","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1196112"],"award-info":[{"award-number":["1196112"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.isci.2026.117642","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:01:15Z","timestamp":1790618475000},"page":"117642","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tregs transduced with a Ro60-reactive TCR have increased immunosuppressive functions in Sj\u00f6gren\u2019s disease"],"prefix":"10.1016","volume":"29","author":[{"given":"Zhi Feng","family":"Sherman Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6977-1333","authenticated-orcid":false,"given":"Rachel M.Y.","family":"Cheong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien B.","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2211-2404","authenticated-orcid":false,"given":"Khai L.","family":"Loh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanim","family":"Halim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Kwai-Wai Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elean S.V.","family":"Tay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng Rui","family":"Peh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Rischmueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi Tian","family":"Ting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3328-2561","authenticated-orcid":false,"given":"Joshua D.","family":"Ooi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2026.117642_bib1","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2016.47","article-title":"Sjogren syndrome","volume":"2","author":"Brito-Zer\u00f3n","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.isci.2026.117642_bib2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s10238-021-00728-6","article-title":"Sj\u00f6gren\u2019s syndrome: a systemic autoimmune disease","volume":"22","author":"Negrini","year":"2022","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.isci.2026.117642_bib3","doi-asserted-by":"crossref","first-page":"E579","DOI":"10.1503\/cmaj.122037","article-title":"Sj\u00f6gren syndrome","volume":"186","author":"Mavragani","year":"2014","journal-title":"CMAJ (Can. Med. Assoc. J.)"},{"key":"10.1016\/j.isci.2026.117642_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103084","article-title":"Primary Sjogren's syndrome is associated with increased risk of malignancies besides lymphoma: A systematic review and meta-analysis","volume":"21","author":"Zhong","year":"2022","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.isci.2026.117642_bib5","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.rdc.2008.08.003","article-title":"Genes and Sjogren's syndrome","volume":"34","author":"Cobb","year":"2008","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"10.1016\/j.isci.2026.117642_bib6","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.autrev.2015.03.008","article-title":"Google-driven search for big data in autoimmune geoepidemiology: analysis of 394,827 patients with systemic autoimmune diseases","volume":"14","author":"Ramos-Casals","year":"2015","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.isci.2026.117642_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2025.100311","article-title":"Regulatory T cell therapy for Sj\u00f6gren's disease: From pathogenesis to targeted treatment","volume":"11","author":"Lim","year":"2025","journal-title":"J. Transl. Autoimmun."},{"key":"10.1016\/j.isci.2026.117642_bib8","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.4049\/jimmunol.150.8.3615","article-title":"Comparison of HLA class II genes in Caucasoid, Chinese, and Japanese patients with primary Sjogren's syndrome","volume":"150","author":"Kang","year":"1993","journal-title":"J. Immunol."},{"key":"10.1016\/j.isci.2026.117642_bib9","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/03009740500287517","article-title":"HLA class II allele polymorphism in Hungarian patients with primary Sjogren's syndrome","volume":"35","author":"Kov\u00e1cs","year":"2006","journal-title":"Scand. J. Rheumatol."},{"key":"10.1016\/j.isci.2026.117642_bib10","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/acr.22115","article-title":"Epidemiology of primary Sjogren's syndrome in a French multiracial\/multiethnic area","volume":"66","author":"Maldini","year":"2014","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.isci.2026.117642_bib11","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jaut.2010.06.010","article-title":"Salivary epithelial cells from Sjogren's syndrome patients are highly sensitive to anoikis induced by TLR-3 ligation","volume":"35","author":"Manoussakis","year":"2010","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.isci.2026.117642_bib12","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.3390\/jcm9093057","article-title":"Contributions of Major Cell Populations to Sjogren's Syndrome","volume":"9","author":"Witas","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.isci.2026.117642_bib13","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.rdc.2016.03.002","article-title":"Autoantibodies in Sjogren's Syndrome","volume":"42","author":"Fayyaz","year":"2016","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"10.1016\/j.isci.2026.117642_bib14","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1177\/0022034510390811","article-title":"Salivary anti-Ro60 and anti-Ro52 antibody profiles to diagnose Sjogren's Syndrome","volume":"90","author":"Ching","year":"2011","journal-title":"J. Dent. Res."},{"key":"10.1016\/j.isci.2026.117642_bib15","first-page":"398","article-title":"[Study on the relationship between primary Sjogren syndrome and HLA-DRbeta gene]","volume":"36","author":"Wang","year":"1997","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"10.1016\/j.isci.2026.117642_bib16","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.3389\/fimmu.2018.02362","article-title":"Gene Expression Profiling of Lacrimal Glands Identifies the Ectopic Expression of MHC II on Glandular Cells as a Presymptomatic Feature in a Mouse Model of Primary Sjogren's Syndrome","volume":"9","author":"Yin","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.117642_bib17","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1586\/1744666X.2016.1109449","article-title":"Early diagnosis of primary Sjogren's syndrome: EULAR-SS task force clinical recommendations","volume":"12","author":"Brito-Zer\u00f3n","year":"2016","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.isci.2026.117642_bib18","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/rheumatology\/ket349","article-title":"Systemic involvement in primary Sjogren's syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry)","volume":"53","author":"Ramos-Casals","year":"2014","journal-title":"Rheumatology"},{"key":"10.1016\/j.isci.2026.117642_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102062","article-title":"Mortality risk factors in primary Sjogren syndrome: a real-world, retrospective, cohort study","volume":"61","author":"Brito-Zer\u00f3n","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.isci.2026.117642_bib20","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1093\/rheumatology\/kez142","article-title":"Treatment of Sjogren's syndrome: current therapy and future directions","volume":"60","author":"Fox","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.isci.2026.117642_bib21","doi-asserted-by":"crossref","first-page":"7305","DOI":"10.1097\/MS9.0000000000002745","article-title":"Frexalimab (SAR441344) as a potential multiautoimmune disorder tackling mAB targeting the CD40-CD40L pathway undergoing clinical trials: a review","volume":"86","author":"Fatima","year":"2024","journal-title":"Ann. Med. Surg."},{"key":"10.1016\/j.isci.2026.117642_bib22","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/ard-2023-224691","article-title":"Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjogren's syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial","volume":"83","author":"D\u00f6rner","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.isci.2026.117642_bib23","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/art.27314","article-title":"Effectiveness of rituximab treatment in primary Sjogren's syndrome: a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Meijer","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.isci.2026.117642_bib24","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1002\/art.40093","article-title":"Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjogren's Syndrome","volume":"69","author":"Bowman","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.isci.2026.117642_bib25","doi-asserted-by":"crossref","DOI":"10.1186\/ar4359","article-title":"Efficacy and safety of rituximab treatment in early primary Sjogren's syndrome: a prospective, multi-center, follow-up study","volume":"15","author":"Carubbi","year":"2013","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.isci.2026.117642_bib26","article-title":"Altered subgroups of regulatory T cells in patients with primary Sjogren's syndrome","volume":"9","author":"Lin","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.isci.2026.117642_bib27","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1365-3083.2009.02308.x","article-title":"How do regulatory T cells work?","volume":"70","author":"Corthay","year":"2009","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.isci.2026.117642_bib28","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41577-019-0232-6","article-title":"T(reg) cell-based therapies: challenges and perspectives","volume":"20","author":"Raffin","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.isci.2026.117642_bib29","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/imcb.12424","article-title":"Antigen-driven CD4(+) T-cell anergy: a pathway to peripheral T regulatory cells","volume":"99","author":"Eggenhuizen","year":"2021","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.isci.2026.117642_bib30","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/s41467-024-45056-x","article-title":"Smith-specific regulatory T cells halt the progression of lupus nephritis","volume":"15","author":"Eggenhuizen","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2026.117642_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.05.017","article-title":"Regulatory T cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetes","volume":"103","author":"Tenspolde","year":"2019","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.isci.2026.117642_bib32","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn1716","article-title":"Pancreatic islet-specific engineered T(regs) exhibit robust antigen-specific and bystander immune suppression in type 1 diabetes models","volume":"14","author":"Yang","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.isci.2026.117642_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clim.2014.02.004","article-title":"T cell epitope mimicry between Sjogren's syndrome Antigen A (SSA)\/Ro60 and oral, gut, skin and vaginal bacteria","volume":"152","author":"Szymula","year":"2014","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.isci.2026.117642_bib34","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/378457a0","article-title":"The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3","volume":"378","author":"Ghosh","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.117642_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.104215","article-title":"Deciphering the landscape of phosphorylated HLA-II ligands","volume":"25","author":"Solleder","year":"2022","journal-title":"iScience"},{"key":"10.1016\/j.isci.2026.117642_bib36","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1600-065X.2011.01018.x","article-title":"Regulatory T cells and Foxp3","volume":"241","author":"Rudensky","year":"2011","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.isci.2026.117642_bib37","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nrrheum.2014.105","article-title":"TREG-cell therapies for autoimmune rheumatic diseases","volume":"10","author":"Miyara","year":"2014","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.isci.2026.117642_bib38","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/eji.202149318","article-title":"Helios is a marker, not a driver, of human Treg stability","volume":"52","author":"Lam","year":"2022","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.isci.2026.117642_bib39","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/eji.201847935","article-title":"Helios(+) and Helios(-) Treg subpopulations are phenotypically and functionally distinct and express dissimilar TCR repertoires","volume":"49","author":"Thornton","year":"2019","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.isci.2026.117642_bib40","series-title":"Services USDoHaH","article-title":"Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs): Guidance for Industry","author":"USFaD","year":"2020"},{"key":"10.1016\/j.isci.2026.117642_bib41","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1002\/acr.24597","article-title":"Antibodies to Both Ro52 and Ro60 for Identifying Sjogren's Syndrome Patients Best Suited for Clinical Trials of Disease-Modifying Therapies","volume":"74","author":"Arma\u011fan","year":"2022","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.isci.2026.117642_bib42","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1136\/annrheumdis-2016-209952","article-title":"Influence of geolocation and ethnicity on the phenotypic expression of primary Sjogren's syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data Sjogren Project Consortium","volume":"76","author":"Brito-Zer\u00f3n","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.isci.2026.117642_bib43","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1046\/j.1365-3083.2001.00993.x","article-title":"Associations of MHC class II alleles in Norwegian primary Sjogren's syndrome patients: implications for development of autoantibodies to the Ro52 autoantigen","volume":"54","author":"Nakken","year":"2001","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.isci.2026.117642_bib44","first-page":"725","article-title":"DRB1\u221715 and DRB1\u221703 extended haplotype interaction in primary Sjogren's syndrome genetic susceptibility","volume":"16","author":"Jean","year":"1998","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.isci.2026.117642_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1298815","article-title":"Concurrent remission of lymphoma and Sjogren's disease following anti-CD19 chimeric antigen receptor-T cell therapy for diffuse large B-cell lymphoma: a case report","volume":"14","author":"Sheng","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.117642_bib46","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1756-8722-4-50","article-title":"The four types of Tregs in malignant lymphomas","volume":"4","author":"Wang","year":"2011","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.isci.2026.117642_bib47","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.2353\/ajpath.2008.080246","article-title":"Foxp3+ T-regulatory cells in Sjogren's syndrome: correlation with the grade of the autoimmune lesion and certain adverse prognostic factors","volume":"173","author":"Christodoulou","year":"2008","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.isci.2026.117642_bib48","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.clim.2017.04.018","article-title":"Genetics of Sjogren's syndrome","volume":"182","author":"Teos","year":"2017","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.isci.2026.117642_bib49","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jaut.2015.07.002","article-title":"Type I and II interferon signatures in Sjogren's syndrome pathogenesis: Contributions in distinct clinical phenotypes and Sjogren's related lymphomagenesis","volume":"63","author":"Nezos","year":"2015","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.isci.2026.117642_bib50","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.3390\/ijms22063090","article-title":"Role of the Innate Immunity Signaling Pathway in the Pathogenesis of Sjogren's Syndrome","volume":"22","author":"Shimizu","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.isci.2026.117642_bib51","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/art.40737","article-title":"Adoptive Treg Cell Therapy in a Patient With Systemic Lupus Erythematosus","volume":"71","author":"Dall'Era","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.isci.2026.117642_bib52","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adn2404","article-title":"A phase 2 randomized trial with autologous polyclonal expanded regulatory T cells in children with new-onset type 1 diabetes","volume":"16","author":"Bender","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.isci.2026.117642_bib53","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1111\/ajt.14415","article-title":"Polyclonal Regulatory T Cell Therapy for Control of Inflammation in Kidney Transplants","volume":"17","author":"Chandran","year":"2017","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.isci.2026.117642_bib54","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1600-0714.2008.00700.x","article-title":"Activation of innate immune responses through Toll-like receptor 3 causes a rapid loss of salivary gland function","volume":"38","author":"Deshmukh","year":"2009","journal-title":"J. Oral Pathol. Med."},{"key":"10.1016\/j.isci.2026.117642_bib55","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.autrev.2011.10.002","article-title":"HLA and Sjogren's syndrome susceptibility. A meta-analysis of worldwide studies","volume":"11","author":"Cruz-Tapias","year":"2012","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.isci.2026.117642_bib56","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.kint.2025.01.005","article-title":"Engineered antigen-specific T regulatory cells suppress autoreactivity to the anti-glomerular basement membrane disease antigen","volume":"107","author":"Eggenhuizen","year":"2025","journal-title":"Kidney Int."},{"key":"10.1016\/j.isci.2026.117642_bib57","doi-asserted-by":"crossref","first-page":"7015","DOI":"10.3390\/ijms21197015","article-title":"Treg Enhancing Therapies to Treat Autoimmune Diseases","volume":"21","author":"Eggenhuizen","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.isci.2026.117642_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2025.103590","article-title":"ROS-dependent SOCS3 upregulation disrupts regulatory T cell stability during autoimmune disease development","volume":"82","author":"Satooka","year":"2025","journal-title":"Redox Biol."},{"key":"10.1016\/j.isci.2026.117642_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104778","article-title":"Dysregulated anti-oxidant signalling and compromised mitochondrial integrity negatively influence regulatory T cell function and viability in liver disease","volume":"95","author":"Vaikunthanathan","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.isci.2026.117642_bib60","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/2526174","article-title":"Oxidative Stress and Treg and Th17 Dysfunction in Systemic Lupus Erythematosus","volume":"2016","author":"Yang","year":"2016","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.isci.2026.117642_bib61","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/s41586-022-05531-1","article-title":"Non-viral precision T cell receptor replacement for personalized cell therapy","volume":"615","author":"Foy","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.117642_bib62","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.1016\/j.cell.2024.06.027","article-title":"Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis","volume":"187","author":"Wang","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.isci.2026.117642_bib63","article-title":"Harnessing TCR repertoires: predictive insights and therapeutic monitoring in cancer immunotherapy","volume":"28","author":"Chiffelle","year":"2025","journal-title":"Immunooncol. Technol."}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226030233?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226030233?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T21:37:28Z","timestamp":1794346648000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004226030233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":63,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2589004226030233"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2026.117642","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tregs transduced with a Ro60-reactive TCR have increased immunosuppressive functions in Sj\u00f6gren\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2026.117642","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117642"}}